Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the maximum tolerated dose, dose-limiting toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in patients with non-small cell lung cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: R-Pharm
• Treatments: Carboplatin; Epothilones

Criteria

Inclusion Criteria:

• Age ≥20 years

• Histologic or cytologic diagnosis of advanced non-small cell lung cancer (NSCLC)

• Advanced NSCLC, defined as stage IIIB (without indications for radiotherapy), stage IV, or recurrent

• No prior chemotherapy-containing regimens for the treatment of NSCLC

• Eastern Cooperative Oncology Group performance status of 0-1

• Life expectancy of at least 12 weeks

• Accessible for treatment and follow up; patients who could be hospitalized for first 15 days of Cycle 1

• Adequate recovery from previous systemic therapy (at least 3 weeks for surgery or radiation therapy)

Exclusion Criteria:

• Women of childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for study period and for up to 4 weeks after last dose of study drug

• Women pregnant or breast feeding

• Women with a positive pregnancy test result on enrollment or prior to study drug administration

• Sexually active fertile men not using effective birth control for the entire study period and for up to 3 months after the last dose of study drug if their partners are WOCBP

• Patients with symptomatic or requiring treatment for brain metastases and/or leptomeningeal metastases

• Prior radiation must not have included ≥30% of major bone-marrow-containing areas (pelvis, lumbar spine)

• Common Terminology Criteria (CTC) Grade 2 or greater neuropathy

• Psychiatric or other disorders rendering the patient incapable of complying with protocol requirements

• Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix (Patients with a history of malignancy but without evidence of disease for 5 years are eligible)

• Serious uncontrolled medical disorder or active systemic infection that would impair the ability of the subject to receive protocol therapy.

• Myocardial infarction, unstable angina, or unstable congestive heart failure within 6 months

• Known history of infection with human immunodeficiency virus

• Inadequate bone marrow function

• Inadequate hepatic function

• Inadequate renal function

• Known prior severe hypersensitivity reaction (CTC Grade 2 or greater) to agents containing Cremophor®EL

• Known severe hypersensitivity reaction to agents containing carboplatin and other platinum

• Prior treatment with an epothilone and/or with platinum

• History of high-dose chemotherapy with bone marrow transplant or peripheral blood stem cell support within 2 years

• On treatment with strong Cytochrome P450 3A4 inhibitor

• Current imprisonment

• Compulsorily detention for treatment of psychiatric or physical illness